Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 OrganiGramAnaptysBioProvention BioRigel PharmaceuticalsCalliditas Therapeutics AB (publ)
Price Information
Current Price$2.52$22.82$7.91$3.66$26.99
52 Week RangeHoldHoldBuyBuyBuy
Overall Score1.
Analysis Score4.
Community Score3.
Dividend Score0.
Ownership Score0.
Earnings & Valuation Score0.
Analyst Ratings
Consensus RecommendationHoldHoldBuyBuyBuy
Consensus Price Target$4.41$30.29$19.75$8.33$40.80
% Upside from Price Target75.05% upside32.72% upside149.68% upside127.69% upside51.17% upside
Trade Information
Market Cap$585.32 million$624.49 million$501.30 million$622.64 million$673.97 million
Average Volume23,077,848515,8291,346,6373,814,34433,135
Sales & Book Value
Annual Revenue$64.61 million$8 millionN/A$59.29 million$19.56 million
Price / Sales9.0678.06N/A10.5034.46
Cashflow$0.02 per shareN/AN/AN/AN/A
Price / Cash101.50N/AN/AN/AN/A
Book Value$1.04 per share$14.93 per share$1.72 per share$0.32 per shareN/A
Price / Book2.421.53N/A11.44
Net Income$-101,290,000.00$-97,340,000.00$-43,280,000.00$-66,890,000.00$-3,450,000.00
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
Net Margins-207.26%N/AN/A-26.25%N/A
Return on Equity (ROE)-10.00%-19.09%-67.66%-44.96%-26.80%
Return on Assets (ROA)-7.14%-17.94%-62.27%-20.08%-25.38%
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt-to-Equity Ratio0.17%N/AN/A0.39%N/A
Current Ratio2.66%14.13%9.23%2.92%23.46%
Quick Ratio3.39%14.13%9.23%2.86%23.46%
Ownership Information
Institutional Ownership Percentage10.84%N/A39.42%82.04%11.85%
Insider Ownership PercentageN/A13.00%14.40%4.72%N/A
Shares Outstanding232.27 million27.37 million63.38 million170.12 million24.97 million
Next Earnings Date7/20/2021 (Estimated)5/5/2021 (Estimated)5/6/2021 (Estimated)5/4/2021 (Estimated)5/13/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableOptionableNot Optionable
4/20/2021OrganiGramCIBCReiterated Rating
4/15/2021OrganiGramStifel NicolausBoost Price Target
4/14/2021OrganiGramRaymond JamesLower Price Target
4/14/2021OrganiGramCanaccord GenuityBoost Price Target
4/13/2021OrganiGramAlliance Global PartnersLower Price Target
4/8/2021OrganiGramBMO Capital MarketsUpgrade
3/11/2021OrganiGramCantor FitzgeraldReiterated Rating
8/10/2020OrganiGramJefferies Financial GroupReiterated Rating
3/22/2021AnaptysBioTruist SecuritiesUpgrade
3/15/2021AnaptysBioWedbushReiterated Rating
3/8/2021AnaptysBioJPMorgan Chase & Co.Downgrade
5/7/2020AnaptysBioCredit Suisse GroupBoost Price Target
3/3/2020AnaptysBioSunTrust BanksLower Price Target
4/19/2021Provention BioHC WainwrightReiterated Rating
4/19/2021Provention BioChardan CapitalLower Price Target
4/15/2021Provention BioSVB LeerinkLower Price Target
4/15/2021Provention BioRoyal Bank of CanadaReiterated Rating
4/9/2021Provention BioOppenheimerReiterated Rating
8/6/2020Rigel PharmaceuticalsCitigroupBoost Price Target
8/18/2020Calliditas Therapeutics AB (publ)Ci CapitalReiterated Rating
(Data available from 4/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.